Publication:
Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study

Simple item page
dc.contributor.authorATASOY, BESTE MELEK
dc.contributor.authorsOnal, C.; Li, Y. X.; Miller, R. C.; Poortmans, P.; Constantinou, N.; Weber, D. C.; Atasoy, B. M.; Igdem, S.; Ozsahin, M.; Ozyar, E.
dc.date.accessioned2022-03-14T10:14:57Z
dc.date.available2022-03-14T10:14:57Z
dc.date.issued2011-01
dc.description.abstractBackground: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.
dc.identifier.doi10.1093/annonc/mdq310
dc.identifier.issn0923-7534
dc.identifier.pubmed20587509
dc.identifier.urihttps://hdl.handle.net/11424/244258
dc.identifier.wosWOS:000285414800023
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofANNALS OF ONCOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectchemotherapy
dc.subjectcombined modality treatment
dc.subjectnon-Hodgkin's lymphoma
dc.subjectprognostic factors
dc.subjectradiotherapy
dc.subjectthyroid lymphoma
dc.subjectB-CELL LYMPHOMA
dc.subjectNON-HODGKINS-LYMPHOMA
dc.subjectMALIGNANT-LYMPHOMA
dc.subjectLOCALIZED INTERMEDIATE
dc.subjectONCOLOGY-GROUP
dc.subjectGLAND
dc.subjectRADIOTHERAPY
dc.subjectCHEMOTHERAPY
dc.subjectTHERAPY
dc.subjectCHOP
dc.titleTreatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
dc.typearticle
dspace.entity.typePublication
local.avesis.idec4c4e9d-9c42-4158-acff-d9d723e7f46d
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages9
oaire.citation.endPage164
oaire.citation.issue1
oaire.citation.startPage156
oaire.citation.titleANNALS OF ONCOLOGY
oaire.citation.volume22
relation.isAuthorOfPublication22ce1b48-93da-4e88-a61e-be24b5e6122a
relation.isAuthorOfPublication.latestForDiscovery22ce1b48-93da-4e88-a61e-be24b5e6122a

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Onal et al. - 2011 - Treatment results and prognostic factors in primar.pdf
Size:
205.39 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs